)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
XORTX Therapeutics
XORTX Therapeutics (XRTX) investor relations material
XORTX Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Mar, 2026
Executive summary
Focused on late-stage clinical development of therapies for gout, autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy, and acute kidney injury (AKI) associated with respiratory virus infection.
Lead program XRx-026 targets allopurinol-intolerant gout patients, with NDA submission planned within 12 months, aiming for a US$700M/year market.
Pipeline includes XRx-008 (ADPKD, orphan drug designation), XRx-101 (AKI in respiratory virus infection), and XRx-225 (diabetic nephropathy).
Recent acquisition of Vectus Biosystems' renal anti-fibrotic program expands pipeline.
Financial highlights
Net loss for 2025: US$2.66M, improved from US$3.31M in 2024 and US$2.16M in 2023.
Accumulated deficit as of Dec 31, 2025: US$23.82M.
Cash and cash equivalents at year-end 2025: US$0.86M (down from US$2.47M in 2024).
Shareholders’ equity at year-end 2025: US$2.08M.
No revenue generated; company remains pre-commercial.
Outlook and guidance
Plans to file NDA for XRx-026 (gout) within 12 months, targeting accelerated approval for XRx-008 (ADPKD).
Ongoing efforts to secure additional funding for clinical development and commercialization.
Strategic focus on expanding pipeline through acquisitions and in-licensing.
Update on XRx-026 bridging study requirements
Explain the VB4-P5 acquisition closing delays
Explain board nominee changes for new financing
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from XORTX Therapeutics
- XRx-026 and XRx-008 target major unmet needs in gout and ADPKD, with strong market potential.XRTX
Investor presentation23 Mar 2026 - Biotech seeks $4.3M for gout drug, faces losses, dilution, and Nasdaq compliance risk.XRTXRegistration Filing13 Feb 2026
- Biotech seeks $3.8M via share/warrant offering to fund late-stage gout drug, with high risk and dilution.XRTXRegistration Filing29 Nov 2025
- Registers shares underlying warrants for kidney disease drug development; proceeds fund clinical trials.XRTXRegistration Filing29 Nov 2025
- NDA for oxypurinol in gout expected H1 2026, targeting a $700M–$2B U.S. market.XRTXStudy Update19 Sep 2025
- Net loss narrowed as R&D ramped up; new funding supports late-stage clinical progress.XRTXQ2 202525 Aug 2025
- XRx-026 and XRx-008 advance toward major regulatory milestones in high-value renal markets.XRTXInvestor Presentation2 Jul 2025
- Net loss narrowed and new equity raised, but continued funding is critical for ongoing operations.XRTXQ3 202413 Jun 2025
- Q2 2024 net income driven by warrant revaluation, but cash burn continues as R&D advances.XRTXQ2 202413 Jun 2025
Next XORTX Therapeutics earnings date
Q1 202614 May, 2026
XORTX Therapeutics
Next XORTX Therapeutics earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage